Abstract:

In this talk, Dr. Kip Ludwig will discuss his experience developing neuromodulation therapies from initial concept to animal models, through to clinical trials and regulatory approval. He will focus on work at the Wisconsin Institute for Translational Neuroengineering to develop ‘parallel translation’ strategies to understand and improve the predictivity of animal models for success in clinical trials, and accelerate the path from concept to clinical translation.

Biography:

Dr. Ludwig is the Co-Director of the Wisconsin Institute for Translational Neuroengineering (WITNe) and leads the Ludwig Laboratory at the University of Wisconsin within the WITNe structure. The primary focus of his lab is developing next-generation neuromodulation therapies that use minimally invasive strategies to hack the nervous system to treat circuit dysfunction and deliver biomolecules to target areas with unprecedented precision.

Prior to Wisconsin Dr. Ludwig served as the Program Director for Neural Engineering at the National Institutes of Health. He co-led the Translational Devices Program at NINDS, led the White House NIH BRAIN Initiative programs to catalyze implantable academic and clinical devices to stimulate and/or record from the central nervous system, and led a trans-NIH planning team in developing the ~250 million dollar S.P.A.R.C. Program to stimulate advances in neuromodulation therapies for organ systems. He also led the trans-NIH Advanced Neural Prosthetics Program.

Dr. Ludwig also worked in Industry as a research scientist, where his team conceived, developed and demonstrated the chronic efficacy of a next-generation neural stimulation electrode for reducing blood pressure in both pre-clinical studies and clinical trials. Through his industry work he oversaw Good Laboratory Practice (GLP) and non-GLP studies enabling clinical trials in Europe and the United States, as well as participated in the protocol development and execution of those trials, leading to approval for sale in twenty countries including the United States.

Dr. Ludwig connects his academic research to the neuromodulation industry and clinical translation through multiple consulting and advisory roles. He serves as the Chair of the NeuroOne Scientific Advisory Board on Artificial Intelligence, and is a member of the Scientific Advisory Board for Abbott, Battelle, Blackfynn, Cala Health, the National Center for Adaptive Neurotechnologies and Presidio Medical. He is a co-founder of Neuronoff, Inc. and NeuraWorx. Dr. Ludwig is also a paid consultant for NeuroOne, ONWARD, Restora Medical, Presidio Medical, and the Alfred Mann Foundation.

~ BME Faculty Host: Matthew Ward, PhD ~

Zoom Link: https://purdue-edu.zoom.us/j/93634966285

Students registered for the seminar are expected to attend in-person.

MARK YOUR CALENDARS